trial · primary record
Datopotamab deruxtecan
Advanced or Metastatic NSCLC
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 155 |
| Primary completion | 2027-05-04 |
| Primary endpoint | Number of participants with DLTs; TEAEs and other safety parameters during the study. |
| Registry ID | NCT04612751 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:36.898Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04612751
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.